Registration Requirements for Individual Practitioners Operating in a “Locum Tenens” Capacity, 55499-55502 [E9-25937]
Download as PDF
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Proposed Rules
5. Technical reports and evaluations
of any prototype ROVs with enhanced
safety designs.
6. Technical information on ROV/
vehicle design specific to vehicle
handling (e.g., suspension design and
the use of sway bars).
7. Minimum and maximum track
width considerations in ROV design.
8. Minimum and maximum ground
clearance considerations in ROV design.
9. Minimum and maximum speed
considerations in ROV design.
10. Information on the center of
gravity heights of occupied and
unoccupied ROV models currently on
the market.
11. Information about the
applicability of sensor technology to
improve the safety of ROVs.
12. Technical information on
technologies for increasing seat belt use.
13. Technical information on
technologies for increasing the
performance of seat belts.
14. Technical studies and evaluations
of three-point, four-point, and five-point
seat belts.
15. Technical information on ROPS
design as it pertains to ground impact
footprint and potential crushing injuries
to the occupant.
16. Information on test procedures to
evaluate occupant retention and
protection performance during roll over.
17. Information on how non-fatal
injuries associated with ROVs compare
with those associated with ATVs in
terms of severity and type of injury.
mstockstill on DSKH9S0YB1PROD with PROPOSALS
List of Relevant Documents
1. Briefing memorandum from
Caroleene Paul, Project Manager,
Directorate for Engineering Sciences, to
the Commission, ‘‘Advance Notice of
Proposed Rulemaking (ANPR) for
Recreational Off-Highway Vehicles
(ROVs),’’ September 25, 2009.
2. Memorandum from Caroleene Paul,
Division of Mechanical Engineering,
CPSC, to Robert J. Howell, Assistant
Executive Director for Hazard
Identification and Reduction,
‘‘Recreational Off-Highway Vehicles
(ROVs),’’ September 25, 2009.
3. Memorandum from Sarah Garland,
Mathematical Statistician, Division of
Hazard Analysis, CPSC, and Robin
Streeter, Mathematical Statistician,
Division of Hazard Analysis, CPSC, to
Caroleene Paul, Project Manager,
Directorate for Engineering Sciences,
‘‘Review of Reported Injuries and
Fatalities Associated with Recreational
Off-Highway Vehicles (ROVs),’’
September 2009.
4. Memorandum from Robert
Franklin, Economist, Directorate for
Economic Analysis, CPSC, to Caroleene
VerDate Nov<24>2008
16:11 Oct 27, 2009
Jkt 220001
Paul, Project Manager, Directorate for
Engineering Sciences, ‘‘Recreational OffHighway Vehicles: Market Information,’’
September 25, 2009.
Dated: October 22, 2009.
Todd A. Stevenson,
Secretary, Consumer Product Safety
Commission.
[FR Doc. E9–25959 Filed 10–27–09; 8:45 am]
BILLING CODE 6355–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1301
[Docket No. DEA–324a]
RIN 1117–AB21
Registration Requirements for
Individual Practitioners Operating in a
‘‘Locum Tenens’’ Capacity
AGENCY: Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Advance notice of proposed
rulemaking.
Summary: On December 1, 2006, the
Drug Enforcement Administration
(DEA) published in the Federal Register
a Final Rule ‘‘Clarification of
Registration Requirements for
Individual Practitioners’’ (71 FR 69478).
The Final Rule makes it clear that when
an individual practitioner practices in
more than one State, he or she must
obtain a separate DEA registration for
each State. The Final Rule also noted
that DEA would address its policy
regarding locum tenens practitioners in
a separate future document. To
adequately address this issue, DEA is
publishing this Advance Notice of
Proposed Rulemaking to seek
information useful to the agency in
promulgating regulations regarding
locum tenens practitioners.
DATES: Written comments must be
postmarked on or before December 28,
2009, and electronic comments must be
sent on or before midnight Eastern time
December 28, 2009.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–324’’ on all written and
electronic correspondence. Written
comments being sent via regular or
express mail should be sent to the Drug
Enforcement Administration, Attention:
DEA Federal Register Representative/
ODL, 8701 Morrissette Drive,
Springfield, VA 22152. Comments may
be sent to DEA by sending an electronic
message to
PO 00000
Frm 00018
Fmt 4702
Sfmt 4702
55499
dea.diversion.policy@usdoj.gov.
Comments may also be sent
electronically through https://
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
document is also available at the
https://www.regulations.gov Web site.
DEA will accept attachments to
electronic comments in Microsoft Word,
WordPerfect, Adobe PDF, or Excel file
formats only. DEA will not accept any
file formats other than those specifically
listed here.
Please note that DEA is requesting
that electronic comments be submitted
before midnight Eastern Time on the
day the comment period closes because
https://www.regulations.gov terminates
the public’s ability to submit comments
at midnight Eastern Time on the day the
comment period closes. Commenters in
time zones other than Eastern Time may
want to consider this so that their
electronic comments are received. All
comments sent via regular or express
mail will be considered timely if
postmarked on the day the comment
period closes.
FOR FURTHER INFORMATION CONTACT:
Mark W. Caverly, Chief, Liaison and
Policy Section, Office of Diversion
Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152; telephone: (202)
307–7297.
SUPPLEMENTARY INFORMATION: Posting of
Public Comments: Please note that all
comments received are considered part
of the public record and made available
for public inspection online at https://
www.regulations.gov and in the Drug
Enforcement Administration’s public
docket. Such information includes
personal identifying information (such
as your name, address, etc.) voluntarily
submitted by the commenter.
If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want posted online or made
available in the public docket in the first
paragraph of your comment and identify
what information you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
E:\FR\FM\28OCP1.SGM
28OCP1
55500
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Proposed Rules
mstockstill on DSKH9S0YB1PROD with PROPOSALS
of your comment. You must also
prominently identify confidential
business information to be redacted
within the comment. If a comment has
so much confidential business
information that it cannot be effectively
redacted, all or part of that comment
may not be posted online or made
available in the public docket.
Personal identifying information and
confidential business information
identified and located as set forth above
will be redacted and the comment, in
redacted form, will be posted online and
placed in the Drug Enforcement
Administration’s public docket file.
Please note that the Freedom of
Information Act applies to all comments
received. If you wish to inspect the
agency’s public docket file in person by
appointment, please see the ‘‘For
Further Information’’ paragraph.
DEA’s Legal Authority
DEA implements and enforces the
Comprehensive Drug Abuse Prevention
and Control Act of 1970, often referred
to as the Controlled Substances Act
(CSA) and the Controlled Substances
Import and Export Act (CSIEA), (21
U.S.C. 801–971), as amended. DEA
publishes the implementing regulations
for these statutes in Title 21 of the Code
of Federal Regulations (CFR), Parts 1300
to end. These regulations are designed
to ensure that there is a sufficient
supply of controlled substances for
medical, scientific, and other legitimate
purposes and to deter the diversion of
controlled substances to illegal
purposes.
Controlled substances are drugs that
have a potential for abuse and
psychological and physical dependence;
these include substances classified as
opioids, stimulants, depressants,
hallucinogens, anabolic steroids, and
drugs that are immediate precursors of
these classes of substances. DEA lists
controlled substances in 21 CFR part
1308. The substances are divided into
five schedules: Schedule I substances
have a high potential for abuse and have
no accepted medical use in treatment in
the United States. These substances may
only be used for research, chemical
analysis, or manufacture of other drugs.
Schedule II–V substances have an
accepted medical use and also have a
potential for abuse and psychological
and physical dependence.
The CSA mandates that DEA establish
a closed system of control for
manufacturing, distribution, and
dispensing of controlled substances.
Any person who manufactures,
distributes, dispenses, imports, exports,
or conducts research or chemical
analysis with controlled substances
VerDate Nov<24>2008
16:11 Oct 27, 2009
Jkt 220001
must register with DEA (unless exempt),
keep track of all stocks of controlled
substances, and maintain records to
account for all controlled substances
received, distributed, dispensed, or
otherwise disposed of.
Background
The CSA defines ‘‘dispense’’ as
meaning ‘‘to deliver a controlled
substance to an ultimate user or
research subject by, or pursuant to the
lawful order of, a practitioner, including
the prescribing and administering of a
controlled substance * * *’’ (21 U.S.C.
802(10)). The CSA requires that every
person who dispenses controlled
substances shall obtain from the
Attorney General a registration (21
U.S.C. 822(a)(2)). Authority to issue
such registrations has been delegated by
the Attorney General to the
Administrator of the Drug Enforcement
Administration (28 CFR 0.100). DEA has
established, by regulation, that the
period of registration for persons who
dispense controlled substances is three
years (21 CFR 1301.13(e)(iv)).
The CSA states that the Attorney
General shall register practitioners to
dispense controlled substances if the
applicant for registration is authorized
to dispense controlled substances under
the laws of the State in which the
applicant practices (21 U.S.C. 823(f)).
The Attorney General may deny an
application for registration if he
determines that the issuance of
registration would be inconsistent with
the public interest. In determining the
public interest, the Attorney General is
required to consider the following
factors:
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The applicant’s experience in
dispensing, or conducting research with
respect to controlled substances.
(3) The applicant’s conviction record under
Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety. (21 U.S.C.
823(f))
The CSA further requires that a
separate registration be obtained for
each principal place of business or
professional practice where controlled
substances are manufactured,
distributed, or dispensed (21 U.S.C.
822(e)). DEA has provided a limited
exception to this requirement (21 CFR
1301.12(b)(3)): Practitioners who
register at one location, but practice at
other locations within the same State,
PO 00000
Frm 00019
Fmt 4702
Sfmt 4702
are not required to register for any other
location in that State at which they only
prescribe controlled substances.
The exception applies only to
additional locations within the same
State in which the practitioner
maintains his DEA registration. DEA
individual practitioner registrations are
based on a State license to practice
medicine and prescribe controlled
substances. DEA relies on State
licensing boards to determine that
practitioners are qualified to administer,
dispense, or prescribe controlled
substances and to determine what level
of authority practitioners have, that is,
what schedules they may administer,
dispense, or prescribe. State authority to
conduct the above-referenced activities
only confers rights and privileges within
the issuing State; consequently, the DEA
registration based on a State license
cannot authorize controlled substance
dispensing outside the State.
DEA discussed the intrastate
exception extensively in a Notice of
Proposed Rulemaking ‘‘Clarification of
Registration Requirements for
Individual Practitioners’’ [Docket No.
DEA–244, RIN 1117–AA89] (69 FR
70576, December 7, 2004) and in a
subsequent Final Rule (71 FR 69478,
December 1, 2006). This rule clarified
that the exception discussed above
related only to intrastate, as opposed to
interstate, locations.
Locum Tenens Practitioners
DEA received three comments to its
December 7, 2004, Notice of Proposed
Rulemaking requesting clarification of
the effect of that rule on the practice of
‘‘locum tenens’’ practitioners. Locum
tenens is a procedure whereby someone
substitutes temporarily for another.
Latin for ‘‘to hold the place of, to
substitute for,’’ locum tenens means, in
layman’s terms, a temporary physician
or other practitioner. Usually, locum
tenens practitioners contract with a
staffing company to perform medical
services for a healthcare organization for
a specified length of time. The
practitioner is paid by the staffing firm
itself, which is then paid by the
healthcare facility, i.e., the client.
Groups supportive of locum tenens
indicate that the practice of locum
tenens benefits both practitioners and
healthcare organizations because it
provides flexibility for both parties.
They note that the industry offers
temporary opportunities for medical
professionals across the country and
worldwide. DEA has found one estimate
indicating that there are over 100 locum
tenens agencies operating in the United
States and over 30,000 locum tenens
practitioners. The practitioners in
E:\FR\FM\28OCP1.SGM
28OCP1
mstockstill on DSKH9S0YB1PROD with PROPOSALS
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Proposed Rules
demand are hospital-based specialties
including anesthesiology, psychiatry,
radiology, pediatrics, and surgery.
The CSA does not specifically
reference or acknowledge the practice of
locum tenens. DEA regulations do make
clear that under 21 CFR 1301.12(a), ‘‘A
separate registration is required for each
principal place of business or
professional practice at one general
physical location where controlled
substances are manufactured,
distributed, imported, or dispensed by a
person.’’ When a locum tenens
practitioner substitutes for another
practitioner on a temporary or sporadic
basis at that other practitioner’s [DEA
registered] place of business, that place
of business is considered by DEA to be
a ‘‘principal place of business or
professional practice’’ for purposes of
the locum tenens practitioner’s DEA
registration (21 CFR 1301.12(a)).
Since DEA individual practitioner
registrations are based on State
authority to practice and prescribe
controlled substances, a practitioner is
not authorized to dispense controlled
substances outside the State(s) in which
he or she is licensed and registered.
Therefore, any locum tenens practice
that is conducted in a State other than
the State in which the practitioner
maintains his DEA registration is subject
to a separate DEA registration.
DEA believes that two alternatives
presently exist to obtain a separate DEA
registration in another State to
accommodate a locum tenens practice.
First, if the practitioner is licensed to
practice and to handle controlled
substances in that second state, he may
submit an address change for his current
DEA registration for the temporary
practice location. There is no cost to
change an address, even temporarily,
and it generally takes one week to
process. At the end of the locum tenens
practice, the practitioner may submit a
request to change his address to his new
primary place of business, within the
same state.
Second, if the locum tenens service is
with a hospital or other institution
registered with DEA, if the hospital
agrees, and if State law allows, the
practitioner may use the DEA
registration of that hospital or other
institution to administer, dispense, or
prescribe controlled substances so long
as all requirements are met (21 CFR
1301.22(c)). Specifically:
An individual practitioner who is an agent
or employee of a hospital or other institution
may, when acting in the normal course of
business or employment, administer,
dispense, or prescribe controlled substances
under the registration of the hospital or other
VerDate Nov<24>2008
16:11 Oct 27, 2009
Jkt 220001
institution which is registered in lieu of
being registered himself, provided that:
(1) Such dispensing, administering or
prescribing is done in the usual course of his
professional practice;
(2) Such individual practitioner is
authorized or permitted to do so by the
jurisdiction in which he is practicing;
(3) The hospital or other institution by
whom he is employed has verified that the
individual practitioner is so permitted to
dispense, administer, or prescribe drugs
within the jurisdiction;
(4) Such individual practitioner is acting
only within the scope of his employment in
the hospital or institution;
(5) The hospital or other institution
authorizes the individual practitioner to
administer, dispense or prescribe under the
hospital registration and designates a specific
internal code number for each individual
practitioner so authorized. The code number
shall consist of numbers, letters, or a
combination thereof and shall be a suffix to
the institution’s DEA registration number,
preceded by a hyphen (e.g., APO123456–10
or APO123456–A12); and
(6) A current list of internal codes and the
corresponding individual practitioners is
kept by the hospital or other institution and
is made available at all times to other
registrants and law enforcement agencies
upon request for the purpose of verifying the
authority of the prescribing individual
practitioner. (21 CFR 1301.22(c))
This waiver places the controlled
substance registration and
recordkeeping responsibility with the
hospital or other institution; therefore,
there is no need for individual DEA
registration. However, the individual
practitioner must still maintain State
licensure.
State Regulations
As DEA discussed in its proposed and
final rules regarding the clarification of
registration by individual practitioners
(69 FR 70576, December 7, 2004; 71 FR
69478, December 1, 2006), the issuance
by DEA of an individual practitioner
registration is predicated, in part, on the
practitioner being authorized (e.g.,
licensed) to dispense controlled
substances by the State in which he
practices (21 U.S.C. 823(f)). Valid State
authority to dispense controlled
substances is a necessary, but not
sufficient, condition for obtaining a DEA
registration. DEA will not register a
practitioner at a particular location
within a State if the practitioner lacks
valid State authority to dispense
controlled substances in that State. DEA
registration serves, in part, to reflect that
the individual practitioner has been
granted some level of controlled
substances authority by the State. In
light of the above, a DEA registration is
considered to be related directly and
exclusively to the license issued to the
practitioner by the State in which he
PO 00000
Frm 00020
Fmt 4702
Sfmt 4702
55501
maintains the registration. These
principles are discussed extensively in
DEA’s proposed and final rules
referenced above.
While DEA is aware that a few States
have legislation or regulations regarding
the locum tenens industry, DEA does
not believe that the information it has
regarding States’ legislation and/or
regulations is complete. DEA notes that
States may address locum tenens under
general legislative authority and through
a variety of State regulatory entities,
including State boards of medicine and
State licensing commissions. Therefore,
as discussed further below, DEA is
specifically seeking information from
State regulatory authorities regarding
States’ legislative and/or regulatory
requirements for locum tenens
practitioners, agencies, and entities that
contract with these persons.
Comments Requested
DEA is soliciting information from the
locum tenens industry so that DEA may
obtain a better understanding of this
industry and how it functions. DEA
seeks to clarify the requirements that
apply to locum tenens practitioners,
especially after considering the
December 2006 final rule that specified
that only intrastate locations are subject
to the exception for registration at
separate locations. Commenters are
encouraged to include the comment
number enumerated below in their
response. Although all comments are
welcome, DEA is particularly interested
in comments regarding the questions
listed below. These questions are
separated into groups by area of interest.
The groups are:
• Locum tenens practitioners
• Those that employ and place locum
tenens practitioners
• Institutions that retain the services of
locum tenens practitioners
• State regulatory authorities
Locum Tenens Practitioners
1. In your experience, what types of
practitioners participate in locum
tenens activities (e.g., physicians,
dentists, nurse practitioners)? Please
specify your type of licensure.
2. How long is the typical locum
tenens assignment?
3. Do locum tenens practitioners seek
State/Federal licensure or registration
prior to accepting a position as a locum
tenens practitioner?
4. What is the length of time between
hiring for the position and reporting to
duty?
5. Do practitioners secure locum
tenens positions independently or
through an agency?
E:\FR\FM\28OCP1.SGM
28OCP1
55502
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Proposed Rules
6. As locum tenens practitioners, do
you administer, dispense and prescribe
controlled substances? Does your
authority to do so vary in the States in
which you practice?
7. Can you have more than one locum
tenens job at a time?
Those That Employ and Place Locum
Tenens Practitioners
8. What role do you have in the locum
tenens process?
9. Do you assist with State and
Federal licensure/registration? If so,
how?
10. What types of practitioners do you
employ or place (e.g., physicians,
dentists, nurse practitioners)?
11. How do you verify the locum
tenens practitioner’s credentials?
12. Are criminal background checks
performed on locum tenens
practitioners?
13. What is the geographical coverage
for locum tenens (e.g., local, statewide,
multi-state, national)?
14. How much time is there between
assignments for one practitioner?
Institutions That Retain the Services of
Locum Tenens Practitioners
mstockstill on DSKH9S0YB1PROD with PROPOSALS
15. How many locum tenens
placement agencies do you contract
with?
16. How frequently do you secure
locum tenens services?
17. What credentialing checks do you
perform on the locum tenens
practitioners working for you? Do you
perform fewer checks for practitioners
supplied by agencies than you do for
practitioners you contract with
individually?
18. For how long do you secure locum
tenens services (i.e., duration)?
19. For what specialties do you use
locum tenens practitioners?
20. What authority do you grant
locum tenens practitioners? (For
example, can they administer, dispense,
or prescribe controlled substances?
Under whose DEA registration would
such an activity occur?)
21. Do you grant locum tenens
practitioners the same controlled
substance authority that other
practitioners using the institution’s DEA
registration to dispense controlled
substances have? If not, why not?
State Regulatory Authorities
22. What are the State requirements
for locum tenens practice for
practitioners (e.g., physicians, dentists)?
23. Does the State waive State medical
licensure (or automatically grant
temporary courtesy licensure) for locum
tenens practitioners if they are properly
licensed in another State? If so, what
VerDate Nov<24>2008
16:11 Oct 27, 2009
Jkt 220001
checks are performed to confirm State
licensure in the other State?
24. If granted, for how long is the
waiver or courtesy licensure?
25. What are the State requirements
for locum tenens practice for mid-level
practitioners (e.g., physician assistants,
nurse practitioners)?
26. Does the State waive State
licensure (or automatically grant
temporary courtesy licensure) for locum
tenens practitioners who are mid-level
practitioners if they are properly
licensed in another State? If so, what
checks are performed to confirm State
licensure in the other State?
27. If granted, for how long is the
waiver or courtesy licensure?
28. If the State requires State licensure
with the medical or other professional
board, how long is it good for?
29. Does the State grant locum tenens
practitioners the same controlled
substance authority that it grants to
practitioners that are fully licensed by
the State professional board? If not, why
not?
30. To dispense controlled
substances, must a locum tenens
practitioner obtain a State controlled
substance registration?
31. Does the State medical or other
professional board report board actions
against locum tenens practitioners to the
National Practitioner database and to
States in which the locum tenens
practitioner holds a license?
Regulatory Certifications
This action is an Advance Notice of
Proposed Rulemaking (ANPRM).
Accordingly, the requirement of
Executive Order 12866 to assess the
costs and benefits of this action does not
apply. Rather, among the purposes DEA
has in publishing this ANPRM is to seek
information from the public regarding
locum tenens practitioners. Similarly,
the requirements of section 603 of the
Regulatory Flexibility Act do not apply
to this action since, at this stage, it is an
ANPRM and not a ‘‘rule’’ as defined in
section 601 of the Regulatory Flexibility
Act. Following review of the comments
received to this ANPRM, if DEA
promulgates a Notice or Notices of
Proposed Rulemaking regarding this
issue, DEA will conduct all analyses
required by the Regulatory Flexibility
Act, Executive Order 12866, and any
other statutes or Executive Orders
relevant to those rules and in effect at
the time of promulgation.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control.
[FR Doc. E9–25937 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00021
Fmt 4702
Sfmt 4702
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA–331]
Schedules of Controlled Substances:
Placement of 5-Methoxy-N,NDimethyltryptamine Into Schedule I of
the Controlled Substances Act
AGENCY: Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Notice of proposed rulemaking;
reopening of comment period.
SUMMARY: On August 21, 2009, the Drug
Enforcement Administration (DEA)
published a notice of proposed
rulemaking in the Federal Register, 74
FR 42217, to place the substance 5methoxy-N,N-dimethyltryptamine (5MeO-DMT) and its salts into schedule I
of the Controlled Substances Act (CSA).
The original 30-day comment period
expired on September 21, 2009. DEA is
reopening the comment period for an
additional 30-day period.
DATES: Written comments must be
postmarked, and electronic comments
must be sent, on or before November 27,
2009. Commenters should be aware that
the electronic Federal Docket
Management System will not accept
comments after midnight Eastern time
on the last day of the comment period.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–331’’ on all written and
electronic correspondence. Written
comments being sent via regular or
express mail should be sent to the Drug
Enforcement Administration, Attention:
DEA Federal Register Representative/
ODL, 8701 Morrissette Drive,
Springfield, VA 22152. Comments may
be sent to DEA by sending an electronic
message to
dea.diversion.policy@usdoj.gov.
Comments may also be sent
electronically through https://
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
document is also available at the
https://www.regulations.gov Web site.
DEA will accept electronic comments
containing Microsoft Word,
WordPerfect, Adobe PDF, or Excel files
only. DEA will not accept any file
format other than those specifically
listed here.
Please note that DEA is requesting
that electronic comments be submitted
before midnight Eastern time on the day
the comment period closes because
E:\FR\FM\28OCP1.SGM
28OCP1
Agencies
[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Proposed Rules]
[Pages 55499-55502]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25937]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1301
[Docket No. DEA-324a]
RIN 1117-AB21
Registration Requirements for Individual Practitioners Operating
in a ``Locum Tenens'' Capacity
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Advance notice of proposed rulemaking.
-----------------------------------------------------------------------
Summary: On December 1, 2006, the Drug Enforcement Administration
(DEA) published in the Federal Register a Final Rule ``Clarification of
Registration Requirements for Individual Practitioners'' (71 FR 69478).
The Final Rule makes it clear that when an individual practitioner
practices in more than one State, he or she must obtain a separate DEA
registration for each State. The Final Rule also noted that DEA would
address its policy regarding locum tenens practitioners in a separate
future document. To adequately address this issue, DEA is publishing
this Advance Notice of Proposed Rulemaking to seek information useful
to the agency in promulgating regulations regarding locum tenens
practitioners.
DATES: Written comments must be postmarked on or before December 28,
2009, and electronic comments must be sent on or before midnight
Eastern time December 28, 2009.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-324'' on all written and electronic correspondence.
Written comments being sent via regular or express mail should be sent
to the Drug Enforcement Administration, Attention: DEA Federal Register
Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152.
Comments may be sent to DEA by sending an electronic message to
dea.diversion.policy@usdoj.gov. Comments may also be sent
electronically through https://www.regulations.gov using the electronic
comment form provided on that site. An electronic copy of this document
is also available at the https://www.regulations.gov Web site. DEA will
accept attachments to electronic comments in Microsoft Word,
WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept
any file formats other than those specifically listed here.
Please note that DEA is requesting that electronic comments be
submitted before midnight Eastern Time on the day the comment period
closes because https://www.regulations.gov terminates the public's
ability to submit comments at midnight Eastern Time on the day the
comment period closes. Commenters in time zones other than Eastern Time
may want to consider this so that their electronic comments are
received. All comments sent via regular or express mail will be
considered timely if postmarked on the day the comment period closes.
FOR FURTHER INFORMATION CONTACT: Mark W. Caverly, Chief, Liaison and
Policy Section, Office of Diversion Control, Drug Enforcement
Administration, 8701 Morrissette Drive, Springfield, VA 22152;
telephone: (202) 307-7297.
SUPPLEMENTARY INFORMATION: Posting of Public Comments: Please note that
all comments received are considered part of the public record and made
available for public inspection online at https://www.regulations.gov
and in the Drug Enforcement Administration's public docket. Such
information includes personal identifying information (such as your
name, address, etc.) voluntarily submitted by the commenter.
If you want to submit personal identifying information (such as
your name, address, etc.) as part of your comment, but do not want it
to be posted online or made available in the public docket, you must
include the phrase ``PERSONAL IDENTIFYING INFORMATION'' in the first
paragraph of your comment. You must also place all the personal
identifying information you do not want posted online or made available
in the public docket in the first paragraph of your comment and
identify what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be posted online or made available
in the public docket, you must include the phrase ``CONFIDENTIAL
BUSINESS INFORMATION'' in the first paragraph
[[Page 55500]]
of your comment. You must also prominently identify confidential
business information to be redacted within the comment. If a comment
has so much confidential business information that it cannot be
effectively redacted, all or part of that comment may not be posted
online or made available in the public docket.
Personal identifying information and confidential business
information identified and located as set forth above will be redacted
and the comment, in redacted form, will be posted online and placed in
the Drug Enforcement Administration's public docket file. Please note
that the Freedom of Information Act applies to all comments received.
If you wish to inspect the agency's public docket file in person by
appointment, please see the ``For Further Information'' paragraph.
DEA's Legal Authority
DEA implements and enforces the Comprehensive Drug Abuse Prevention
and Control Act of 1970, often referred to as the Controlled Substances
Act (CSA) and the Controlled Substances Import and Export Act (CSIEA),
(21 U.S.C. 801-971), as amended. DEA publishes the implementing
regulations for these statutes in Title 21 of the Code of Federal
Regulations (CFR), Parts 1300 to end. These regulations are designed to
ensure that there is a sufficient supply of controlled substances for
medical, scientific, and other legitimate purposes and to deter the
diversion of controlled substances to illegal purposes.
Controlled substances are drugs that have a potential for abuse and
psychological and physical dependence; these include substances
classified as opioids, stimulants, depressants, hallucinogens, anabolic
steroids, and drugs that are immediate precursors of these classes of
substances. DEA lists controlled substances in 21 CFR part 1308. The
substances are divided into five schedules: Schedule I substances have
a high potential for abuse and have no accepted medical use in
treatment in the United States. These substances may only be used for
research, chemical analysis, or manufacture of other drugs. Schedule
II-V substances have an accepted medical use and also have a potential
for abuse and psychological and physical dependence.
The CSA mandates that DEA establish a closed system of control for
manufacturing, distribution, and dispensing of controlled substances.
Any person who manufactures, distributes, dispenses, imports, exports,
or conducts research or chemical analysis with controlled substances
must register with DEA (unless exempt), keep track of all stocks of
controlled substances, and maintain records to account for all
controlled substances received, distributed, dispensed, or otherwise
disposed of.
Background
The CSA defines ``dispense'' as meaning ``to deliver a controlled
substance to an ultimate user or research subject by, or pursuant to
the lawful order of, a practitioner, including the prescribing and
administering of a controlled substance * * *'' (21 U.S.C. 802(10)).
The CSA requires that every person who dispenses controlled substances
shall obtain from the Attorney General a registration (21 U.S.C.
822(a)(2)). Authority to issue such registrations has been delegated by
the Attorney General to the Administrator of the Drug Enforcement
Administration (28 CFR 0.100). DEA has established, by regulation, that
the period of registration for persons who dispense controlled
substances is three years (21 CFR 1301.13(e)(iv)).
The CSA states that the Attorney General shall register
practitioners to dispense controlled substances if the applicant for
registration is authorized to dispense controlled substances under the
laws of the State in which the applicant practices (21 U.S.C. 823(f)).
The Attorney General may deny an application for registration if he
determines that the issuance of registration would be inconsistent with
the public interest. In determining the public interest, the Attorney
General is required to consider the following factors:
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The applicant's experience in dispensing, or conducting
research with respect to controlled substances.
(3) The applicant's conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety. (21 U.S.C. 823(f))
The CSA further requires that a separate registration be obtained
for each principal place of business or professional practice where
controlled substances are manufactured, distributed, or dispensed (21
U.S.C. 822(e)). DEA has provided a limited exception to this
requirement (21 CFR 1301.12(b)(3)): Practitioners who register at one
location, but practice at other locations within the same State, are
not required to register for any other location in that State at which
they only prescribe controlled substances.
The exception applies only to additional locations within the same
State in which the practitioner maintains his DEA registration. DEA
individual practitioner registrations are based on a State license to
practice medicine and prescribe controlled substances. DEA relies on
State licensing boards to determine that practitioners are qualified to
administer, dispense, or prescribe controlled substances and to
determine what level of authority practitioners have, that is, what
schedules they may administer, dispense, or prescribe. State authority
to conduct the above-referenced activities only confers rights and
privileges within the issuing State; consequently, the DEA registration
based on a State license cannot authorize controlled substance
dispensing outside the State.
DEA discussed the intrastate exception extensively in a Notice of
Proposed Rulemaking ``Clarification of Registration Requirements for
Individual Practitioners'' [Docket No. DEA-244, RIN 1117-AA89] (69 FR
70576, December 7, 2004) and in a subsequent Final Rule (71 FR 69478,
December 1, 2006). This rule clarified that the exception discussed
above related only to intrastate, as opposed to interstate, locations.
Locum Tenens Practitioners
DEA received three comments to its December 7, 2004, Notice of
Proposed Rulemaking requesting clarification of the effect of that rule
on the practice of ``locum tenens'' practitioners. Locum tenens is a
procedure whereby someone substitutes temporarily for another. Latin
for ``to hold the place of, to substitute for,'' locum tenens means, in
layman's terms, a temporary physician or other practitioner. Usually,
locum tenens practitioners contract with a staffing company to perform
medical services for a healthcare organization for a specified length
of time. The practitioner is paid by the staffing firm itself, which is
then paid by the healthcare facility, i.e., the client.
Groups supportive of locum tenens indicate that the practice of
locum tenens benefits both practitioners and healthcare organizations
because it provides flexibility for both parties. They note that the
industry offers temporary opportunities for medical professionals
across the country and worldwide. DEA has found one estimate indicating
that there are over 100 locum tenens agencies operating in the United
States and over 30,000 locum tenens practitioners. The practitioners in
[[Page 55501]]
demand are hospital-based specialties including anesthesiology,
psychiatry, radiology, pediatrics, and surgery.
The CSA does not specifically reference or acknowledge the practice
of locum tenens. DEA regulations do make clear that under 21 CFR
1301.12(a), ``A separate registration is required for each principal
place of business or professional practice at one general physical
location where controlled substances are manufactured, distributed,
imported, or dispensed by a person.'' When a locum tenens practitioner
substitutes for another practitioner on a temporary or sporadic basis
at that other practitioner's [DEA registered] place of business, that
place of business is considered by DEA to be a ``principal place of
business or professional practice'' for purposes of the locum tenens
practitioner's DEA registration (21 CFR 1301.12(a)).
Since DEA individual practitioner registrations are based on State
authority to practice and prescribe controlled substances, a
practitioner is not authorized to dispense controlled substances
outside the State(s) in which he or she is licensed and registered.
Therefore, any locum tenens practice that is conducted in a State other
than the State in which the practitioner maintains his DEA registration
is subject to a separate DEA registration.
DEA believes that two alternatives presently exist to obtain a
separate DEA registration in another State to accommodate a locum
tenens practice. First, if the practitioner is licensed to practice and
to handle controlled substances in that second state, he may submit an
address change for his current DEA registration for the temporary
practice location. There is no cost to change an address, even
temporarily, and it generally takes one week to process. At the end of
the locum tenens practice, the practitioner may submit a request to
change his address to his new primary place of business, within the
same state.
Second, if the locum tenens service is with a hospital or other
institution registered with DEA, if the hospital agrees, and if State
law allows, the practitioner may use the DEA registration of that
hospital or other institution to administer, dispense, or prescribe
controlled substances so long as all requirements are met (21 CFR
1301.22(c)). Specifically:
An individual practitioner who is an agent or employee of a
hospital or other institution may, when acting in the normal course
of business or employment, administer, dispense, or prescribe
controlled substances under the registration of the hospital or
other institution which is registered in lieu of being registered
himself, provided that:
(1) Such dispensing, administering or prescribing is done in the
usual course of his professional practice;
(2) Such individual practitioner is authorized or permitted to
do so by the jurisdiction in which he is practicing;
(3) The hospital or other institution by whom he is employed has
verified that the individual practitioner is so permitted to
dispense, administer, or prescribe drugs within the jurisdiction;
(4) Such individual practitioner is acting only within the scope
of his employment in the hospital or institution;
(5) The hospital or other institution authorizes the individual
practitioner to administer, dispense or prescribe under the hospital
registration and designates a specific internal code number for each
individual practitioner so authorized. The code number shall consist
of numbers, letters, or a combination thereof and shall be a suffix
to the institution's DEA registration number, preceded by a hyphen
(e.g., APO123456-10 or APO123456-A12); and
(6) A current list of internal codes and the corresponding
individual practitioners is kept by the hospital or other
institution and is made available at all times to other registrants
and law enforcement agencies upon request for the purpose of
verifying the authority of the prescribing individual practitioner.
(21 CFR 1301.22(c))
This waiver places the controlled substance registration and
recordkeeping responsibility with the hospital or other institution;
therefore, there is no need for individual DEA registration. However,
the individual practitioner must still maintain State licensure.
State Regulations
As DEA discussed in its proposed and final rules regarding the
clarification of registration by individual practitioners (69 FR 70576,
December 7, 2004; 71 FR 69478, December 1, 2006), the issuance by DEA
of an individual practitioner registration is predicated, in part, on
the practitioner being authorized (e.g., licensed) to dispense
controlled substances by the State in which he practices (21 U.S.C.
823(f)). Valid State authority to dispense controlled substances is a
necessary, but not sufficient, condition for obtaining a DEA
registration. DEA will not register a practitioner at a particular
location within a State if the practitioner lacks valid State authority
to dispense controlled substances in that State. DEA registration
serves, in part, to reflect that the individual practitioner has been
granted some level of controlled substances authority by the State. In
light of the above, a DEA registration is considered to be related
directly and exclusively to the license issued to the practitioner by
the State in which he maintains the registration. These principles are
discussed extensively in DEA's proposed and final rules referenced
above.
While DEA is aware that a few States have legislation or
regulations regarding the locum tenens industry, DEA does not believe
that the information it has regarding States' legislation and/or
regulations is complete. DEA notes that States may address locum tenens
under general legislative authority and through a variety of State
regulatory entities, including State boards of medicine and State
licensing commissions. Therefore, as discussed further below, DEA is
specifically seeking information from State regulatory authorities
regarding States' legislative and/or regulatory requirements for locum
tenens practitioners, agencies, and entities that contract with these
persons.
Comments Requested
DEA is soliciting information from the locum tenens industry so
that DEA may obtain a better understanding of this industry and how it
functions. DEA seeks to clarify the requirements that apply to locum
tenens practitioners, especially after considering the December 2006
final rule that specified that only intrastate locations are subject to
the exception for registration at separate locations. Commenters are
encouraged to include the comment number enumerated below in their
response. Although all comments are welcome, DEA is particularly
interested in comments regarding the questions listed below. These
questions are separated into groups by area of interest. The groups
are:
Locum tenens practitioners
Those that employ and place locum tenens practitioners
Institutions that retain the services of locum tenens
practitioners
State regulatory authorities
Locum Tenens Practitioners
1. In your experience, what types of practitioners participate in
locum tenens activities (e.g., physicians, dentists, nurse
practitioners)? Please specify your type of licensure.
2. How long is the typical locum tenens assignment?
3. Do locum tenens practitioners seek State/Federal licensure or
registration prior to accepting a position as a locum tenens
practitioner?
4. What is the length of time between hiring for the position and
reporting to duty?
5. Do practitioners secure locum tenens positions independently or
through an agency?
[[Page 55502]]
6. As locum tenens practitioners, do you administer, dispense and
prescribe controlled substances? Does your authority to do so vary in
the States in which you practice?
7. Can you have more than one locum tenens job at a time?
Those That Employ and Place Locum Tenens Practitioners
8. What role do you have in the locum tenens process?
9. Do you assist with State and Federal licensure/registration? If
so, how?
10. What types of practitioners do you employ or place (e.g.,
physicians, dentists, nurse practitioners)?
11. How do you verify the locum tenens practitioner's credentials?
12. Are criminal background checks performed on locum tenens
practitioners?
13. What is the geographical coverage for locum tenens (e.g.,
local, statewide, multi-state, national)?
14. How much time is there between assignments for one
practitioner?
Institutions That Retain the Services of Locum Tenens Practitioners
15. How many locum tenens placement agencies do you contract with?
16. How frequently do you secure locum tenens services?
17. What credentialing checks do you perform on the locum tenens
practitioners working for you? Do you perform fewer checks for
practitioners supplied by agencies than you do for practitioners you
contract with individually?
18. For how long do you secure locum tenens services (i.e.,
duration)?
19. For what specialties do you use locum tenens practitioners?
20. What authority do you grant locum tenens practitioners? (For
example, can they administer, dispense, or prescribe controlled
substances? Under whose DEA registration would such an activity occur?)
21. Do you grant locum tenens practitioners the same controlled
substance authority that other practitioners using the institution's
DEA registration to dispense controlled substances have? If not, why
not?
State Regulatory Authorities
22. What are the State requirements for locum tenens practice for
practitioners (e.g., physicians, dentists)?
23. Does the State waive State medical licensure (or automatically
grant temporary courtesy licensure) for locum tenens practitioners if
they are properly licensed in another State? If so, what checks are
performed to confirm State licensure in the other State?
24. If granted, for how long is the waiver or courtesy licensure?
25. What are the State requirements for locum tenens practice for
mid-level practitioners (e.g., physician assistants, nurse
practitioners)?
26. Does the State waive State licensure (or automatically grant
temporary courtesy licensure) for locum tenens practitioners who are
mid-level practitioners if they are properly licensed in another State?
If so, what checks are performed to confirm State licensure in the
other State?
27. If granted, for how long is the waiver or courtesy licensure?
28. If the State requires State licensure with the medical or other
professional board, how long is it good for?
29. Does the State grant locum tenens practitioners the same
controlled substance authority that it grants to practitioners that are
fully licensed by the State professional board? If not, why not?
30. To dispense controlled substances, must a locum tenens
practitioner obtain a State controlled substance registration?
31. Does the State medical or other professional board report board
actions against locum tenens practitioners to the National Practitioner
database and to States in which the locum tenens practitioner holds a
license?
Regulatory Certifications
This action is an Advance Notice of Proposed Rulemaking (ANPRM).
Accordingly, the requirement of Executive Order 12866 to assess the
costs and benefits of this action does not apply. Rather, among the
purposes DEA has in publishing this ANPRM is to seek information from
the public regarding locum tenens practitioners. Similarly, the
requirements of section 603 of the Regulatory Flexibility Act do not
apply to this action since, at this stage, it is an ANPRM and not a
``rule'' as defined in section 601 of the Regulatory Flexibility Act.
Following review of the comments received to this ANPRM, if DEA
promulgates a Notice or Notices of Proposed Rulemaking regarding this
issue, DEA will conduct all analyses required by the Regulatory
Flexibility Act, Executive Order 12866, and any other statutes or
Executive Orders relevant to those rules and in effect at the time of
promulgation.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control.
[FR Doc. E9-25937 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P